South Africa has the world’s largest ARV program, currently providing treatment to around 2.7 million people in the public health sector and over 150,000 in the private sectors (as at December 2013).
“Ketlaphela Pharmaceutical SOC Ltd ‘‘Ketlaphela’’ was created in response to the cabinet’s directive for the country to have its own State owned pharmaceutical company. Increasing local manufacturing to decrease reliance and risks associated with high level of imports for this important sector has been a priority for government that ultimately led to the call for the Ketlaphela Project.
The State owned pharmaceutical company is premised on supplying South African manufactured Active Pharmaceutical Ingredients (APIs) and final formulated medical products mainly for communicable diseases such as HIV/AIDS, Tuberculosis, and Malaria and later non-communicable diseases”. Product availability and hence security of supply will likely improve due to a closer working relationship between the Dept. of Health and a state owned company.
The socio-economic benefits of Ketlaphela are job creation, technology transfer, reduction in the balance of Trade in pharmaceuticals through effective localization, capacity building and improving the affordability of treatments for high burden diseases, such as HIV, Tuberculosis and some non-communicable diseases.
Our vision is to be a leader in the delivery of quality and affordable medicines to the local market.
• To be the preferred supplier of local medicine
• Deliver on our promises, safely and in an
environmentally responsible manner.
• Driving growth through Excellence, Innovation,
Performance and Customer Focus.
Ketlaphela Pharmaceuticals Leadership
Mr Ivan Radebe is the Managing Director of Ketlaphela Pharmaceuticals SOC Ltd and serves as an executive director on the board of directors. He is a member of the Engineering Council of South Africa (ECSA) and the Institute of Directors in Southern Africa (IoDSA). He is an internationally trained and experienced executive with expertise in Asset Maintenance & Management, Infrastructure Project Development, Sales & Marketing, Operations & Strategic Leadership. He previously worked for PetroSA, National Department of Public Works, General Electric, Eskom and NTP Europe in Belgium. He has Masters in Strategy and Project Management from Université Paris 1 Panthéon-Sorbonne, a B-Eng(Honors)- Electrical/Electronics from the University Teknologi PETRONAS, National Diploma in Electrical Engineering from Vaal University of Technology, MDP from UNISA and EDP from University of Stellenbosch Business School.
Ms Letsoalo served as NTP Group Executive: Strategy & Risk Management for 6 months prior to joining AEC-Amersham. She was Executive Manager: Stakeholder Relations, Risk Management & IT at NTP Radioisotopes SOC Ltd, from 2012 to 2014. She previously managed the radiopharmaceuticals division in which Tc-99m generators, I-131 products, sterile cold kits and Fluorodeoxyglucose (FDG), are manufactured. Ms Letsoalo has extensive radioisotope production experience which spans between 1999 and 2011.
She has over five (5) years’ experience as a Board member having served on the NTP Radioisotopes Board for 5 years (2007 – 2012). She also served as a member of the Boards of Directors of Gammatec NDT Supplies SOC Ltd (2013 to 2015) and AEC-Amersham (2013 to 2015), both of which are subsidiaries of NTP Radioisotopes.
Ms Letsoalo was educated at the University of South Africa Business School (UNISA) where she acquired a Masters Degree in Business Leadership (MBL) in 2007/08. She completed her first degree in Pharmacy acquired at the then University of the North (now referred to as University of Limpopo) in 1996.